Table 2.
Solicited (reactogenicity subset) and unsolicited adverse events, SAEs and AESIs (full safety set).
| Adverse events | ChAdOx1-S full dose |
ChAdOx1-S half dose |
BNT162b2 half dose |
|---|---|---|---|
| n = 101 | n = 105 | n = 114 | |
| Solicited adverse events, n (%)a | |||
| Local | 52 (51.5) | 40 (38.1) | 48 (42.1) |
| Systemic | 56 (55.4) | 52 (49.5) | 54 (47.4) |
| N = 231 | N = 236 | N = 234 | |
| Unsolicited adverse events, n (%)b | |||
| Any | 53 (22.9) | 63 (26.7) | 69 (29.5) |
| Related | 10 (4.3) | 8 (3.4) | 8 (3.4) |
| Severe (Grade 3) | 3 (1.3) | 2 (0.8) | 2 (0.9) |
| Related and severe | 0 | 0 | 0 |
| Serious adverse events (SAE), n (%)b | |||
| Any | 2 (0.9) | 2 (0.8) | 2 (0.9) |
| Related | 0 | 0 | 0 |
| Adverse event of special interest (AESI), n (%)b | |||
| 0 | 0 | 1 (1.0) | |
a: Solicited AEs in Days 0–7 after vaccination.
b: Unsolicited AEs up to Day 28 post-vaccination, SAEs and AESIs up to data cutoff.